Rheumatoid arthritis: Effective disease control cuts mortalityBiologics may offer an advantage over conventional disease-modifying drugs Rheumatologists and their patients leery of subsequent-entry biologicsResearcher cites lack of North American trials as a concern Arthritis Research Centre of Canada receives CIHR Partnership Award for arthritis screening program Osteoporosis: Better drugs needed Bone density falls despite long-term oral bisphosphonate therapy Rheumatoid arthritis: Triple-drug combo could save millions Treatment is just as effective as a biologic, while much cheaper Celebrex generics now launching in Canada Health Canada approves several generic versions of celecoxib. Tapered therapy maintains remission in rheumatoid arthritis Strategy addresses safety and cost concerns, but requires vigilant monitoring Gout linked with increased diabetes risk Study supports proper recognition and management of risk factors, researchers say Diclofenac maximum recommended dose reduced from 150 mg to 100 mg daily Lower dose intended to improve cardiovascular safety of systemic diclofenac products. Xeljanz: first oral JAK inhibitor for rheumatoid arthritis Used for moderately to severely active disease in adults with an inadequate response to methotrexate. First Previous 13 14 15 16 17 Next Last
